| | Values | HR | p value |
|---|
Median age (Yr) | 59 (38 – 72) | 1.04 | 0.16 |
Gender | | | |
M | 65% | 0.89 | 0.85 |
F | 35% | | |
ECOG PS (%) | | 1.04 | 0.92 |
0 | 30 | | |
1 | 60 | | |
2 | 10 | | |
3 & 4 | 0 | | |
N° of Sites | | 0.80 | 0.74 |
1 | 75% | | |
2 | 25% | | |
>2 | 0% | | |
Initial Sites | | 0.99 | 0.99 |
liver | 15% | | |
lung | 10% | | |
peritoneal | 20% | | |
local | 25% | | |
nodal | 0% | | |
bone | 5% | | |
combinations | 25% | | |
- Median age was determined at diagnosis of metastatic disease or at documentation of recurrence. M = male; F = female; ECOG PS Performance Status according to Eastern Cooperative Oncology Group; NO of Sites = number of metastatic sites at diagnosis of metastatic disease or recurrence; Initial Sites = Proportion of initial metastatic/recurrent sites according to the involved organ. HR = Hazard ratio for Overall Survival after univariate analysis. P value = level of significance.
